Ileostomy Market Size & Share 2026-2035

Ileostomy Market Size

The global ileostomy market was valued at USD 1.3 billion in 2025 and is projected to rise from approximately USD 1.4 billion in 2026 to USD 2.1 billion by 2035, expanding at a 4.9% CAGR.

An ileostomy diverts intestinal output through a stoma created from the ileum. The market includes one-piece and two-piece pouching systems, as well as accessories such as skin barriers, rings, pastes, powders, adhesive removers, protective wipes, belts, and odor-control products. Unlike a one-time surgical product market, ileostomy care creates repeat demand. A patient with a permanent end ileostomy requires an ongoing combination of collection, adhesion, and skin-protection products, making retention and clinical performance central to supplier economics.

The addressable clinical pool continues to broaden. An estimated 13.5 million people worldwide live with a stoma ^{[1]newsfromwales.co.uk, World's Largest Ostomy Bag Production Line Set to Transform Production at Eakin Healthcare, June 2025, newsfromwales.co.uk}. The World Health Organization recorded approximately 1.9 million new colorectal cancer cases in 2022 ^{[2]who.int, Colorectal Cancer Fact Sheet, 2022, who.int}, while IARC estimated more than 2.0 million new colorectal cancer cases in 2024. Ileostomies are used in selected colorectal cancer resections, severe inflammatory bowel disease procedures, and emergency bowel-diversion settings. Demand is therefore shaped by both the incidence of diseases requiring surgery and the effectiveness of long-term stoma management after discharge.

The principal commercial boundary is peristomal skin performance. Leakage, adhesive trauma, and poor fit can move a patient from loyal repeat use into switching behavior or reduced adherence. Product suppliers that combine effective barrier systems with fitting education, home-delivery support, and early leak-management tools are better placed to protect recurring revenue than those competing only on pouch price. Our market estimates show global value rising to USD 2,103 million by 2035, with growth increasingly weighted toward clinically differentiated systems and accessory-led care routines.

Key Drivers

Increasing prevalence of inflammatory bowel diseases

Inflammatory bowel disease expands the ileostomy patient pool through severe ulcerative colitis and Crohn's disease cases requiring bowel diversion, colectomy, or resection. GBD 2021 data recorded 375,140 new IBD cases globally in 2021, up 88.3% from 1990, while prevalent cases reached 3.83 million ^{[3]pmc.ncbi.nlm.nih.gov, Global, Regional, and National Burden of Inflammatory Bowel Disease, 1990-2021: Insights from the GBD 2021, 2024, pmc.ncbi.nlm.nih.gov}. The disease burden is also shifting beyond historically high-prevalence Western markets. China recorded the fastest increase in age-standardized IBD incidence in the underlying GBD analysis, while India had the largest number of new IBD cases in 2021. A separate global analysis identifies Europe as having the highest pooled IBD prevalence, at 348.4 per 100,000 population.

The market consequence is cumulative rather than immediate. Patients with medically refractory ulcerative colitis may require proctocolectomy and a permanent end ileostomy or a temporary loop ileostomy. Crohn's disease can require diversion where fistulizing disease, perianal complications, or irreversible bowel damage limit conventional treatment. As disease prevalence rises in Asia Pacific and other developing care markets, manufacturers must build clinical education and distribution capacity before demand matures into high-value recurring product use.

Aging population and rise in surgical interventions

Population aging increases the number of people exposed to colorectal cancer, bowel obstruction, ischemic colitis, and complex surgical care. The global population aged 65 years and above totaled 833.5 million in 2024. The United Nations projects that the population aged 65 years and above will increase from 761 million in 2021 to 1.6 billion by 2050, while the WHO expects one in six people worldwide to be aged 60 years or over by 2030.

Older patients are particularly relevant because they may require longer periods of post-surgical appliance use and often need products that simplify application, removal, and skin management. China had 208.1 million people aged 65 years and above in 2024, while India had more than 100 million. These demographic pools support Asia Pacific's higher forecast growth rate, even as mature European markets retain a substantial need for long-term care products.

Technological advancements in ostomy products

Innovation is moving competition beyond basic pouch containment toward seal integrity, skin protection, fit, and discreet self-management. ConvaTec launched Esteem Body with Leak Defense in the United States in April 2024. The soft-convex one-piece system is offered in two depths and four tension widths to accommodate different body contours and support a more durable seal. The subsequent UK launch in September 2024 extended the platform into another major ostomy market.

Coloplast introduced Heylo, SenSura Mio Black, and SenSura Mio Convex Soft with Flex coupling during 2024. Heylo uses a sensor and paired smartphone application to notify the user of leakage at the barrier-skin interface. That proposition addresses a specific ileostomy-care problem: rapid skin damage can occur when liquid output breaches the adhesive seal. Hollister's CeraPlus range similarly positions ceramide-infused barriers around skin health and prevention of adhesive-related disruption. These advances can support premiumization when clinical performance reduces the practical burden of frequent appliance changes.

Growing focus on awareness programs coupled with favorable reimbursement scenario

Reimbursement and skilled instruction determine whether a prescribed ostomy system becomes a sustainable care routine. In the United States, Medicare Part B covers medically necessary ostomy supplies under the Prosthetic Device benefit. CMS policy details the covered supply categories and documentation requirements applicable to ostomy patients. This framework reduces out-of-pocket barriers for a large older patient cohort and supports regular replenishment through home-delivery channels.

Education creates value alongside coverage. Correct cutting, barrier fitting, pouch-change technique, and early identification of leakage are essential to reducing avoidable skin injury. As health systems shift more post-surgical care into the home, suppliers that support nurses, caregivers, and patients with product-specific training can influence adherence and accessory use. In emerging markets, the opportunity is less about replacing established systems and more about converting under-managed stoma care into standardized product consumption.

Key Restraints

Discomfort and risk of skin irritation and infections

Peristomal skin complications remain the central clinical constraint on ileostomy product adoption and retention. Published evidence reports complication incidence ranging from 36.3% to 73.4% during the first 90 days after ostomy surgery ^{[4]mdpi.com, Peristomal Skin Complications in Ileostomy and Colostomy Patients: What We Need to Know from a Public Health Perspective, 2023, mdpi.com}. A multinational survey found that 88% of people living with an ostomy had experienced a peristomal skin complication, and 75% reported symptoms even without visible discoloration. An international consensus report identified these complications as a major driver of unplanned ostomy-nurse consultations.

Ileostomy patients face a distinctive risk profile because effluent is liquid and contains digestive enzymes that can rapidly damage skin when an appliance seal fails. In a study of recent ostomy patients, peristomal skin complications affected 47.5% of ileostomy patients during the first 90 days, compared with 36.1% of colostomy patients and 15.0% of urinary-diversion patients. Those complications were associated with higher 120-day readmission rates and higher healthcare costs.

This burden shapes purchasing behavior in opposing ways. It increases demand for rings, barrier films, convex systems, and protective accessories, but it can also generate dissatisfaction, repeated switching, and payer scrutiny of premium systems. The restraint is most acute where patients leave hospital without access to trained stoma-care support. Product design and care delivery must therefore work together: an improved adhesive has limited commercial effect if users cannot fit it correctly or recognize leakage early.

Our primary research with ostomy care clinicians indicates that leakage prevention, skin preservation, and confidence in self-management are closely linked in ileostomy product selection. This finding aligns with the market estimate for accessories, which is projected to grow at a 5.4% CAGR, faster than ostomy bags at 4.8%. The implication is not that accessories replace core pouching systems; rather, they increasingly function as a performance layer around them. Suppliers that prove a reduction in leakage-related care burden can strengthen their position with clinicians, patients, and reimbursement stakeholders.

Ileostomy Market Segment Analysis

By Type

End ileostomy generated USD 750.1 million in 2025, accounting for 57.5% of the market, and is projected to reach USD 1,250.6 million by 2035 at a 5.2% CAGR. Its larger value reflects the durable consumption profile of permanent diversion. A permanent end ileostomy creates a long-term need for bags, barriers, and skin-protection products, which gives manufacturers more opportunity to retain users through product fit, service, and clinical support.

Loop ileostomy was valued at USD 405.8 million in 2025 and is forecast to reach approximately USD 645.6 million by 2035 at a 4.7% CAGR. These procedures are often intended to be temporary, particularly when protecting an anastomosis following colorectal surgery or restorative procedures for ulcerative colitis. However, the period of use can still be clinically demanding because high-output liquid effluent raises the importance of a secure, skin-protective seal. Other types represented USD 148.5 million in 2025 and are expected to expand at a 3.3% CAGR, reflecting their more specialized clinical use.

By Product

Ostomy bags accounted for USD 1,083.7 million in 2025 and are projected to grow at a 4.8% CAGR. Two-piece systems represented USD 640.6 million and are expected to expand at a 5.0% CAGR, ahead of one-piece systems at USD 443.0 million and a 4.4% CAGR. The two-piece format allows a pouch to be changed without removing the skin barrier, which can be valuable for users who need frequent pouch changes or are managing vulnerable peristomal skin.

One-piece systems remain important where simplicity, lower profile, and straightforward application are priorities. The launch of advanced soft-convex one-piece products illustrates that the format is no longer limited to basic care. Product selection increasingly depends on the interaction between stoma shape, skin condition, output profile, dexterity, and patient preference rather than on a single system architecture.

Accessories were valued at USD 220.7 million in 2025 and are forecast to expand at the fastest product CAGR of 5.4%. Their growth reflects a shift from treating accessories as optional add-ons toward using them to improve seal reliability and protect skin. This creates an opportunity for suppliers to increase revenue per patient through coordinated pouch, barrier, and accessory regimens, particularly in home care.

By Application

Colorectal cancer represented the largest application segment at USD 479.2 million in 2025 and is projected to grow at a 5.2% CAGR. Rising colorectal cancer incidence supports surgical demand, but an ileostomy is not an automatic outcome of every resection. Product demand depends on tumor location, surgical approach, anastomotic risk, and whether diversion is temporary or permanent. The application remains commercially important because colorectal cancer procedures can initiate long-lasting product use in both older and younger patient populations.

Ulcerative colitis accounted for USD 333.7 million in 2025 and is forecast to grow at a 4.7% CAGR. In severe or treatment-refractory disease, colectomy may create a permanent end ileostomy or a loop ileostomy associated with restorative surgery. Crohn's disease generated USD 267.8 million and is projected to expand at a 5.0% CAGR. Its complex, transmural disease pattern can lead to diversion in fistulizing, perianal, or recurrent disease settings. Other applications, including bowel obstruction, diverticulitis, ischemic colitis, trauma, and congenital conditions, represented USD 223.7 million and are expected to grow at a 4.2% CAGR.

By End Use

Hospitals remained the largest end-use segment at USD 583.2 million in 2025, representing 44.7% of demand, and are forecast to grow at a 4.4% CAGR. Hospitals influence product choice at the point of surgery, during inpatient recovery, and through initial stoma-care teaching. Early appliance familiarity can shape later preference, making institutional contracts and clinician education strategically important. Hollister's SURPASS sole-source contract with Premier illustrates the role of hospital-network access in establishing product availability ^{[5]hollister.com, Hollister Incorporated Awarded SURPASS Sole Source Contract for Enterostomal Therapy Products with Premier, Inc., hollister.com}.

Home care settings generated USD 501.9 million in 2025 and are projected to grow at the fastest end-use CAGR of 5.5%. The segment's expansion reflects a transfer of routine care from inpatient settings to patients, caregivers, specialty distributors, and remote clinical support. In this setting, ease of application and predictable wear time can matter as much as the technical specification of the pouch. Ambulatory surgical centers accounted for USD 132.8 million and are forecast to grow at a 5.1% CAGR, while other end users represented USD 86.5 million and are expected to expand at a 3.8% CAGR.

The channel shift is equally consequential. Home care is projected to grow at 5.5%, above hospitals at 4.4%, moving more product decisions toward users who directly experience wear time, leakage, odor control, and skin comfort. Suppliers with clinically credible education and dependable replenishment services can turn this decentralized setting into a retention advantage. Those relying only on initial hospital placement face a greater risk of post-discharge switching.

Ileostomy Market Regional Analysis

North America

North America generated USD 251.1 million in 2025, representing 19.3% of the global market, and is forecast to grow at a 3.6% CAGR. The region's lower growth rate reflects an established product base rather than weak clinical demand. Reimbursement, specialist care, and broad availability support repeat consumption, while innovation drives replacement and premiumization.

United States

The U.S. market was valued at USD 237.7 million in 2025, up from USD 228.4 million in 2024, and is projected to grow at a 3.4% CAGR. Medicare coverage for medically necessary ostomy supplies supports access for eligible users, while the U.S. has an estimated 2.4 million to 3.1 million adults living with IBD ^{[6]cdc.gov, Inflammatory Bowel Disease: Facts and Stats, 2023, cdc.gov}. The commercial challenge is to demonstrate why advanced barriers, accessories, and digital support create value beyond basic supply coverage.

Canada

Canada is expected to record a 5.3% CAGR. Its growth profile reflects demand for consistent long-term management in a healthcare environment where colorectal cancer, IBD, aging, and specialist surgical care remain relevant demand foundations. Product suppliers must adapt to regional care pathways and procurement arrangements rather than assume that U.S. channel strategies translate directly.

Europe

Europe led the global market at USD 461.2 million in 2025 and is projected to expand at a 3.8% CAGR. The region combines mature ostomy-care infrastructure with the highest pooled regional IBD prevalence globally. Its growth is therefore linked less to first-time access and more to clinical differentiation, aging, and the ability to secure position within structured healthcare and prescription systems.

Germany

Germany contributes to Europe's established demand base through a large aging population, specialist surgical care, and a high need for ongoing post-surgical management. Supplier differentiation is likely to depend on reliability, skin-performance evidence, and compatibility with organized healthcare purchasing.

United Kingdom

The UK is an important market for product innovation and specialist ostomy care. ConvaTec introduced Esteem Body with Leak Defence in the UK in September 2024, and Coloplast identified the UK among the early markets for its 2024 innovation program. Clinical acceptance and patient-support capabilities are particularly relevant where established users can evaluate products based on lived performance.

France

France forms part of Europe's high-prevalence IBD and colorectal-cancer care environment. Demand is supported by the need to manage patients across diagnosis, surgery, recovery, and long-term stoma care, with supplier success dependent on fitting support and product accessibility.

Spain

Spain's role in the European market is shaped by the need for colorectal and inflammatory bowel disease management within a mature regional care setting. Procurement discipline can favor suppliers able to demonstrate product reliability and total care value, rather than only unit-level price.

Italy

Italy's older population supports continuing demand for products designed for long-term and often complex care needs. The country also served as an early launch market for ConvaTec's Esteem Body platform in 2024, indicating the relevance of advanced barrier technologies in established European care environments.

Netherlands

The Netherlands remains relevant to European demand through its mature healthcare setting and the need for clinically supported, patient-centered stoma management. Suppliers that combine dependable products with professional training can compete more effectively than those offering undifferentiated pouch portfolios.

Asia Pacific

Asia Pacific generated USD 425.8 million in 2025 and is expected to record the fastest regional CAGR of 6.2%. The region's growth combines expanding surgical demand with a rapidly increasing older population and rising awareness of standardized ostomy care. It is also where the commercial gap between disease burden and consistent product access remains widest.

China

China has 208.1 million people aged 65 years and above ^{[7]measuredworld.com, Population Aged 65 Years and Over, 2024, measuredworld.com}, and GBD data identify the country as experiencing the fastest increase in age-standardized IBD incidence among the evaluated countries. These factors create a substantial future demand base for colorectal and IBD-related surgery. The market opportunity depends on extending effective post-discharge management beyond major urban treatment centers.

Japan

Japan had 36.9 million people aged 65 years and above in 2024. Its highly aged population supports steady long-term demand for stoma-care products, with clinical performance, ease of use, and skin compatibility remaining important for older users managing chronic care needs.

India

India had one of the largest absolute numbers of new IBD cases in 2021 and a population of more than 100 million people aged 65 years and above. The country represents a high-growth market where disease burden and demographic exposure are expanding faster than standardized product penetration. Commercial progress will depend on affordability, clinician education, and distribution reach beyond leading metropolitan care centers.

Australia

Australia participates in the regional market through established colorectal cancer and IBD care demand. The need for effective long-term management supports advanced products where clinicians and patients place a high value on skin protection and dependable wear.

South Korea

South Korea adds to Asia Pacific demand through aging, specialist medical care, and the continued need for post-surgical colorectal management. As home-based care expands, the ability to offer simple, reliable systems will become more important alongside hospital-based product placement.

Latin America

Latin America was valued at USD 122.0 million in 2025 and is projected to grow at a 5.9% CAGR. Growth reflects a developing care-access environment in which colorectal surgery, aging, and greater recognition of stoma-management needs are expanding the addressable user base. The region requires commercial models that balance reliable clinical performance with affordability and local distribution capacity.

Brazil

Brazil is central to regional demand because of its population scale, growing older cohort, and concentration of specialist care in major urban areas. Its 23.4 million people aged 65 years and above provide a growing base for long-term surgical and chronic-care demand.

Mexico

Mexico's market development is supported by the broader regional need for colorectal and inflammatory bowel disease management. Variability in access to specialist care and ongoing supplies makes channel coverage and clinician education critical to sustained product adoption.

Argentina

Argentina contributes through its established urban healthcare demand, although purchasing conditions can vary with economic circumstances. A balanced product portfolio across core and advanced systems is more defensible than a strategy based solely on premium products.

Middle East and Africa

Middle East and Africa generated USD 44.3 million in 2025 and is forecast to grow at a 5.6% CAGR. The region's smaller market base leaves scope for higher percentage growth as cancer care, surgical capability, and post-discharge management become more widely available.

Saudi Arabia

Saudi Arabia's ileostomy demand is linked to the broader expansion of surgical and chronic-care capacity. Product suppliers have an opportunity to establish clinician relationships and ensure that users can access fitting support after hospital discharge.

United Arab Emirates

The UAE is a relevant Gulf market for advanced medical care and specialized supply distribution. Its commercial potential is tied to the concentration of healthcare providers and the need for reliable products that can support both hospital and home-based care pathways.

South Africa

South Africa represents an important entry point for ileostomy care in sub-Saharan Africa. Demand is shaped by uneven access to specialist services, making product simplicity, supply continuity, and training especially important to reducing preventable complications.

The commercial implication is that one product and channel model will not fit every geography. China and India require scalable education, distribution, and accessible product configurations as clinical demand broadens. Europe, Japan, and North America reward differentiated barriers, accessories, and service capabilities that justify premium positioning. Latin America, the Middle East, and Africa require disciplined market development because supply continuity and practical training can matter more to adoption than the sophistication of an individual pouch design.

Ileostomy Market Share & Competitive Landscape

The global ileostomy market is led by multinational companies with broad pouching portfolios, established clinical relationships, and access to hospital and home-care channels. Competition centers on barrier performance, fit across different stoma profiles, skin preservation, patient education, and supply continuity. Price remains relevant, particularly in tender-driven and emerging markets, but a low-cost product that contributes to leakage or skin injury can carry a higher care burden for patients and providers.

Coloplast competes through the SenSura Mio platform, advanced convexity systems, digital leakage notification, patient support, and international distribution. Its Ostomy Care business reported 6% organic growth in FY2024/25 after 7% organic growth in FY2023/24 ^{[8]cdn.financialreports.eu, Coloplast Annual Report 2024/25, November 2025, cdn.financialreports.eu}. The 2024 launches of Heylo, SenSura Mio Black, and SenSura Mio Convex Soft with Flex coupling demonstrate a strategy that combines clinical performance with lifestyle-oriented product design.

ConvaTec Group combines a large ostomy-care franchise with new product introductions and direct patient-service capabilities. Its Ostomy Care segment generated USD 634 million in 2024 and reported 5.3% organic growth ^{[9]convatecgroup.com, FY24 Preliminary Results, February 2025, convatecgroup.com}. Esteem Body with Leak Defense expands the company's soft-convex one-piece offering and positions ConvaTec around more adaptable fit and leakage prevention.

Hollister is differentiated by CeraPlus ceramide-infused barrier technology, its established ostomy portfolio, and institutional contracting. The company secured a SURPASS sole-source contract with Premier for enterostomal therapy products and later received multiple contract agreements with Premier. These arrangements strengthen access at the point where many patients first learn and adopt a pouching system.

B. Braun offers ostomy appliance systems across ileostomy, colostomy, and urostomy care, including Flexima and Proxima product families. Its wider clinical product presence supports engagement with hospitals that prefer suppliers able to serve multiple care categories.

The remaining competitive field is differentiated by specialist positioning rather than a uniform challenge to global leaders. Alcare serves the Japanese ostomy-care environment with a portfolio aligned to hospital and home-care needs. Cymed Micro Skin is associated with thin-film barrier approaches for users concerned about adhesive residue and sensitive skin. Flexicare participates in ostomy and stoma care through institutional and distribution channels.

Marlen Healthcare focuses on specialist pouching, barriers, and accessories for complex post-surgical requirements. Nu-Hope Labs is positioned around custom-fit barriers and support products for patients with irregular stoma morphology or parastomal hernia-related fitting challenges. Safe n Simple emphasizes accessories and skin-care products that complement primary pouching systems, particularly in self-managed home-care routines.

Salts Healthcare competes as a specialist ostomy supplier with one-piece and two-piece systems, accessories, and patient-support services. Smith+Nephew brings broader wound-management and adhesive expertise that is relevant to peristomal skin-care needs. Torbot Group serves specialty ostomy and urological care through barriers, adhesives, and accessory products. Welland Medical is positioned around skin-friendly materials and pouching systems for prescription and home-delivery channels. Unora Healthcare focuses on comfort, discretion, and user experience for patients whose product choice is shaped by quality-of-life requirements as well as clinical function.

Recent Industry Developments

June 2025: Eakin Healthcare expands ostomy bag production capacity in Cardiff

Eakin Healthcare announced a new ostomy bag production line at its Cardiff facility as part of a broader £60 million manufacturing investment program. The company described the 32-meter line as capable of increasing ostomy bag production capacity fourfold and reducing production waste relative to prior operations. The investment signals that manufacturers are preparing for higher global demand while seeking more efficient, resilient production of high-volume consumables.

April 2024: ConvaTec launches Esteem Body with Leak Defense in the United States

ConvaTec launched Esteem Body with Leak Defense in the United States in April 2024 after an earlier Italian introduction. The soft-convex one-piece system uses Durahesive and Modified Stomahesive adhesive technologies and is offered in two convexity depths and four tension widths. The launch placed a renewed competitive focus on body conformity and leakage prevention, two issues that are especially consequential for ileostomy users with difficult-to-fit stomas.

May 2024: Coloplast introduces three ostomy-care innovations

Coloplast launched Heylo, SenSura Mio Black, and SenSura Mio Convex Soft with Flex coupling in 2024. Heylo's leakage-notification functionality extends competition into digital monitoring, while the pouch and barrier launches address discreet wear and soft-convex support. Together, the releases show how suppliers are targeting both clinical risk reduction and daily quality-of-life concerns.

2024 to 2025: Hollister expands Premier contract access

Hollister secured a SURPASS sole-source contract for enterostomal therapy products with Premier and subsequently received additional multi-year Premier contract agreements. The developments reinforce the strategic importance of group purchasing arrangements in hospital-driven product initiation and ongoing institutional access.